Leqembi is a monoclonal antibody treatment. It targets amyloid plaques in the brain. These plaques are associated with Alzheimer's disease. The drug aims to slow cognitive decline. It has shown promise in clinical trials. However, its long-term effects remain under study. Leqembi represents a advancement in Alzheimer's research. Patients and families are hopeful for improved outcomes.
